These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1525190)

  • 81. [New treatments of hemorrhagic rectocolitis].
    Rambaud JC
    Ann Gastroenterol Hepatol (Paris); 1988; 24(4):173-7. PubMed ID: 2901821
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Acute pancreatitis during oral 5-aminosalicylic acid therapy.
    Fiorentini MT; Fracchia M; Galatola G; Barlotta A; de la Pierre M
    Dig Dis Sci; 1990 Sep; 35(9):1180-2. PubMed ID: 2390934
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Will there be a next generation of sulfasalazine?
    Goldman P
    Gastroenterology; 1982 Nov; 83(5):1138-41. PubMed ID: 6126420
    [No Abstract]   [Full Text] [Related]  

  • 85. [Inhibition of intestinal leukotriene formation as a possible mechanism of action of sulfasalazine, 5-aminosalicylic acid and 4-aminosalicylic acid].
    Peskar BM
    Klin Wochenschr; 1988 Nov; 66(22):1147-50. PubMed ID: 2907066
    [No Abstract]   [Full Text] [Related]  

  • 86. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE; Helmstädter V
    Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
    [No Abstract]   [Full Text] [Related]  

  • 87. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
    Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA
    Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Sulfasalazine and 5-ASA compounds.
    Allgayer H
    Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
    Mardini HA; Lindsay DC; Deighton CM; Record CO
    Gut; 1987 Sep; 28(9):1084-9. PubMed ID: 3678967
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Therapy of chronic inflammatory bowel diseases. Clinical aspects and therapy of drug-induced side effects].
    Dölle W; Daiss W
    Verh Dtsch Ges Inn Med; 1988; 94():184-91. PubMed ID: 2905099
    [No Abstract]   [Full Text] [Related]  

  • 91. Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine.
    Dew MJ; Harries AD; Evans BK; Rhodes J
    Lancet; 1983 Oct; 2(8353):801. PubMed ID: 6137640
    [No Abstract]   [Full Text] [Related]  

  • 92. New salicylate therapies for ulcerative colitis.
    Bruckstein AH
    Postgrad Med; 1990 Sep; 88(3):79-82, 84, 89. PubMed ID: 1975952
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Adverse effects with oral 5-aminosalicyclic acid.
    Fardy JM; Lloyd DA; Reynolds RP
    J Clin Gastroenterol; 1988 Dec; 10(6):635-7. PubMed ID: 2906645
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.
    Sonu I; Lin MV; Blonski W; Lichtenstein GR
    Gastroenterol Clin North Am; 2010 Sep; 39(3):559-99. PubMed ID: 20951918
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity].
    Loizeau E
    Rev Med Suisse Romande; 1995 Nov; 115(11):935-8. PubMed ID: 8525252
    [No Abstract]   [Full Text] [Related]  

  • 96. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K; Williams JG
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Rowasa suspension enema (mesalamine, USP).
    Ciarleglio CA
    Gastroenterol Nurs; 1989; 12(2):122-4. PubMed ID: 2487824
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study.
    Vande Casteele N; Jakate A; McNamee B; Sandborn WJ
    Br J Clin Pharmacol; 2021 Mar; 87(3):1141-1149. PubMed ID: 32671846
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy.
    Parakkal D; Ehrenpreis ED; Thorpe MP; Putt KS; Hannon B
    World J Gastroenterol; 2010 Jan; 16(1):136-7. PubMed ID: 20039462
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Severe chest pain in a pediatric ulcerative colitis patient after 5-aminosalicylic acid therapy.
    Atay O; Radhakrishnan K; Arruda J; Wyllie R
    World J Gastroenterol; 2008 Jul; 14(27):4400-2. PubMed ID: 18666333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.